US Appeals Court Denies Genentech Injunction Over Amgen's 'At Risk' Trastuzumab Launch
Executive Summary
Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.
You may also be interested in...
Amgen’s Mvasi Biosimilar Survives Restraining Order Bid Again
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
US Patent Reform Would Raise Drug Costs
By weakening ways to challenge drug patent thickets, proposed legislation to reform US patent law would extend brand monopolies and increase spending on medicines, the Association for Accessible Medicines is warning.
US Insurer United Rewards Amgen’s Early Entry With Bevacizumab And Trastuzumab
Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: